Glycostem is going to participate Advanced Therapies Congress in London on 24^th May, 2022. Meet us in the following session:

Time: 14:10 GMT +1 
Presentation: Manufacturing genetically modified NK cells

Glycostem Chief Development Officer Volker Huppert is going to present at the 2022 BioProcess International Europe on 17^th May, 2022.

Presentation title: Platform Approaches for Process Understanding Across Different Biopharmaceutical Sectors: Varying Starting Raw Material in ATMP Processes
Session: Cell & Gene Therapy
Time and date: Tuesday, 17^th May 2022 14:15 - 14:45 CET

Glycostem is attending Bio€quity Europe 2022, from the 16^th - 18^th May 2022.

To book one-to-one partnering meeting with our CEO Troels Jordansen, search "Glycostem" in the partnering platform.

Glycostem will join NK2022 to present posters on 15 May, 2022 during the POSTER SESSION I, in Florida, United States.

25  Universal prospects of cryopreserved “off-the-shelf” umbilical cord blood CD34+ progenitor cell-derived NK cell therapeutics: Clinical and preclinical evaluation of GTA002 and genetically modified candidates
Adil D. Duru, Glycostem Therapeutics B.V.

29  Multimodal activation of ex vivo expanded GTA002 NK cells efficiently targets melanoma
Amanda A. Van Vliet, Glycostem Therapeutics

100  Enabling treatment options against colorectal cancer by enhancing functionality of stem cell derived NK cells
Nina Lamers, PhD, Glycostem Therapeutics

Glycostem to present two poster presentations during ISCT 2022 at San Francisco, California, US.

The summit is now taking place till 7 May in San Francisco, US. Our Development Senior Scientist John Veluchamy, PhD is onsite to present the below posters:

Session 930
A FULLY AUTOMATED CD34+ CELLS ENRICHMENT FROM FRESH AND FROZEN UMBILICAL CORD BLOOD FOR CLINICAL SCALE MANUFACTURING OF NK CELLS USING A CLINIMACS PRODIGY PLATFORM

Session 931
A FULLY AUTOMATED NK CELL HARVEST PROCEDURE FOR CLINICAL SCALE MANUFACTURING OF NK CELLS USING A CLINIMACS PRODIGY PLATFORM

Glycostem is going to be present at the Lunch & Learn organized by Pivot Park, taking place on 12^th April 2022.

Glycostem CEO Troels Jordansen will share our uNiK™ closed manufacturing system of NK cells.